AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|
20.5 C
New York
Monday, June 22, 2026

Tag: change

newssourceFORcompanyinformationcontent1marketreleases

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

The Adam Foundation Commits $750,000 to the FIFA Global Citizen Education Fund, Helping Drive the Initiative Past the $50 Million Mark

Announcement made at Global Citizen Live: Rio de Janeiro ahead of the FIFA World Cup FinalLONDON, June 7, 2026 /PRNewswire/ -- The Adam Foundation,...

University of Phoenix researchers publish study examining doctoral students’ attitudes toward AI chatbots and ChatGPT use in higher education

Peer-reviewed study by Center for Educational and Instructional Technology Research team highlights connections between student perceptions of AI, academic integrity concerns and reported chatbot...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Former Pentagon Advisor: “The $2 Stock Sitting on America’s Greatest Untapped Treasure”

The opportunity has a June 30 deadline. One small company holds the key. And most Americans have no idea. 
The opportunity has a June 30 deadline. One small company holds the key. And most Americans have no idea.

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Inturai Ventures Announces Adoption of Semi-Annual Reporting

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)                                                                                                    investor@inturai.comVANCOUVER, BC, June 5, 2026 /CNW/ - Inturai Ventures Corp. (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) (the...

Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State

Each recipient received $3,000 to support their future higher education goals.SANTA ANA, Calif., June 5, 2026 /PRNewswire/ -- Think Together, California's largest nonprofit expanded...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsChange

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers